Higher MicroRNA-221 and Lower MicroRNA-451 Expression Are Associated with Poor Prognosis in Patients with Thyroid Papillary Carcinoma

Overview

Journal An Sist Sanit Navar

Specialty General Medicine

Date 2024 Aug 23

PMID 39177218

Authors

Jiawei Wu

Weimin Sun

Jingyao Shen

Liping Hu

Affiliations

Soon will be listed here.

Abstract

Background: To analyze the relationship between serum microRNA-221 and microRNA-451 expression and the pathological features and prognosis of patients with thyroid papillary carcinoma.

Methods: Cross-sectional study that included 120 patients with papillary thyroid cancer treated at the hospital and 120 healthy volunteers selected as the control group who underwent physical examination. The relative expression levels of microRNA-221 and microRNA-451 were compared between the thyroid papillary carcinoma group (prior to treatment) and the control group. Additionally, microRNA-221 and microRNA-451 expression levels were analyzed in patients with papillary thyroid carcinoma across different pathological characteristics.

Results: Serum microRNA-221 relative levels were significantly higher (p<0.001) in the papillary carcinoma group compared to the control group, while microRNA-451 levels were higher in the control group (p<0.001). In the papillary carcinoma group, microRNA-221 expression was significantly higher in patients with extracapsular invasion (p<0.001), lymphatic metastasis (p=0.003), and poor prognosis (p<0.001). Conversely, microRNA-451 expression was significantly lower (p<0.001) in patients with extracapsular invasion, lymphatic metastasis and poor prognosis. In the multivariate logistic regression analysis, morphological features suggestive of an aggressive clinical behavior (extracapsular invasion and lymphatic metastasis) were related to high expression of microRNA-221 and low expression of microRNA-451 in patients with thyroid papillary carcinoma (p<0.001).

Conclusions: Serum microRNA-221 and microRNA-451 expression levels are significantly higher and lower, respectively, in patients with papillary thyroid carcinoma, particularly in patients with morphological features suggestive of an aggressive clinical behavior (extracapsular invasion and lymphatic metastasis) and, therefore, of a poor prognosis.

References

Sharma P, Gupta A . MicroRNAs: potential biomarkers for diagnosis and prognosis of different cancers. Transl Cancer Res. 2022; 9(9):5798-5818. PMC: 8798648. DOI: 10.21037/tcr-20-1294. View

Wang Z, Zhang H, Zhang P, Li J, Shan Z, Teng W . Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Med Oncol. 2013; 30(2):577. DOI: 10.1007/s12032-013-0577-9. View

Mohr A, Mott J . Overview of microRNA biology. Semin Liver Dis. 2015; 35(1):3-11. PMC: 4797991. DOI: 10.1055/s-0034-1397344. View

celakovsky P, Kovarikova H, Chrobok V, Mejzlik J, Laco J, Vosmikova H . MicroRNA Deregulation in Papillary Thyroid Cancer and its Relationship With BRAF V600E Mutation. In Vivo. 2021; 35(1):319-323. PMC: 7880723. DOI: 10.21873/invivo.12262. View

Filetti S, Durante C, Hartl D, Leboulleux S, Locati L, Newbold K . Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(12):1856-1883. DOI: 10.1093/annonc/mdz400. View

Bai H, Wu S . miR-451: A Novel Biomarker and Potential Therapeutic Target for Cancer. Onco Targets Ther. 2020; 12:11069-11082. PMC: 6924581. DOI: 10.2147/OTT.S230963. View

Liu N, Jiang N, Guo R, Jiang W, He Q, Xu Y . MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma. Mol Cancer. 2013; 12(1):123. PMC: 3853142. DOI: 10.1186/1476-4598-12-123. View

Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A . The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci. 2011; 61(3):187-93. DOI: 10.1016/j.jdermsci.2010.12.010. View

Suresh R, Sethi S, Ali S, Giorgadze T, Sarkar F . Differential Expression of MicroRNAs in Papillary Thyroid Carcinoma and Their Role in Racial Disparity. J Cancer Sci Ther. 2015; 7(5):145-154. PMC: 4570618. DOI: 10.4172/1948-5956.1000340. View

10.

Liang L, Zheng X, Hu M, Cui Y, Zhong Q, Wang S . MiRNA-221/222 in thyroid cancer: A meta-analysis. Clin Chim Acta. 2018; 484:284-292. DOI: 10.1016/j.cca.2018.06.012. View

11.

Gyorki D, Untch B, Tuttle R, Shaha A . Prophylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence. Ann Surg Oncol. 2013; 20(7):2285-9. DOI: 10.1245/s10434-013-2897-6. View

12.

Davey M, Davies M, Lowery A, Miller N, Kerin M . The Role of MicroRNA as Clinical Biomarkers for Breast Cancer Surgery and Treatment. Int J Mol Sci. 2021; 22(15). PMC: 8346977. DOI: 10.3390/ijms22158290. View

13.

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

14.

Di Paolo D, Pontis F, Moro M, Centonze G, Bertolini G, Milione M . Cotargeting of miR-126-3p and miR-221-3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling. Mol Oncol. 2021; 15(11):2969-2988. PMC: 8564655. DOI: 10.1002/1878-0261.13036. View

15.

Yu J, Deng Y, Liu T, Zhou J, Jia X, Xiao T . Lymph node metastasis prediction of papillary thyroid carcinoma based on transfer learning radiomics. Nat Commun. 2020; 11(1):4807. PMC: 7511309. DOI: 10.1038/s41467-020-18497-3. View

16.

Godlewski J, Bronisz A, Nowicki M, Chiocca E, Lawler S . microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle. 2010; 9(14):2742-8. View

17.

Kim Y, Roh S, Lawler S, Friedman A . miR451 and AMPK mutual antagonism in glioma cell migration and proliferation: a mathematical model. PLoS One. 2011; 6(12):e28293. PMC: 3243681. DOI: 10.1371/journal.pone.0028293. View

18.

Min Y, Huang Y, Wei M, Wei X, Chen H, Wang X . Preoperatively Predicting the Central Lymph Node Metastasis for Papillary Thyroid Cancer Patients With Hashimoto's Thyroiditis. Front Endocrinol (Lausanne). 2021; 12:713475. PMC: 8339927. DOI: 10.3389/fendo.2021.713475. View

19.

Sempere L, Azmi A, Moore A . microRNA-based diagnostic and therapeutic applications in cancer medicine. Wiley Interdiscip Rev RNA. 2021; 12(6):e1662. PMC: 8519065. DOI: 10.1002/wrna.1662. View

20.

Khordadmehr M, Jigari-Asl F, Ezzati H, Shahbazi R, Sadreddini S, Safaei S . A comprehensive review on miR-451: A promising cancer biomarker with therapeutic potential. J Cell Physiol. 2019; 234(12):21716-21731. DOI: 10.1002/jcp.28888. View